These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38332108)

  • 81. Ataxia telangiectasia mutated and p21CIP1 modulate cell survival of drug-induced senescent tumor cells: implications for chemotherapy.
    Crescenzi E; Palumbo G; de Boer J; Brady HJ
    Clin Cancer Res; 2008 Mar; 14(6):1877-87. PubMed ID: 18347191
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Osteosarcoma cell intrinsic PD-L2 signals promote invasion and metastasis via the RhoA-ROCK-LIMK2 and autophagy pathways.
    Ren T; Zheng B; Huang Y; Wang S; Bao X; Liu K; Guo W
    Cell Death Dis; 2019 Mar; 10(4):261. PubMed ID: 30886151
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes.
    Liao H; Chen W; Dai Y; Richardson JJ; Guo J; Yuan K; Zeng Y; Xie K
    Front Oncol; 2019; 9():883. PubMed ID: 31572677
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy.
    Wang Y; Du J; Gao Z; Sun H; Mei M; Wang Y; Ren Y; Zhou X
    Br J Cancer; 2023 Mar; 128(7):1196-1207. PubMed ID: 36522474
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status.
    Shin SJ; Jeon YK; Kim PJ; Cho YM; Koh J; Chung DH; Go H
    Ann Surg Oncol; 2016 Feb; 23(2):694-702. PubMed ID: 26464193
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Investigation of pd-l1 (cd274), pd-l2 (pdcd1lg2), and ctla-4 expressions in malignant pleural mesothelioma by immunohistochemistry and real-time polymerase chain reaction methods.
    Sule Kutlar Dursun F; Alabalik U
    Pol J Pathol; 2022; 73(2):111-119. PubMed ID: 36172747
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer.
    Mo Z; Liu J; Zhang Q; Chen Z; Mei J; Liu L; Yang S; Li H; Zhou L; You Z
    Oncol Lett; 2016 Aug; 12(2):944-950. PubMed ID: 27446374
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma.
    Hoffmann F; Zarbl R; Niebel D; Sirokay J; Fröhlich A; Posch C; Holderried TAW; Brossart P; Saavedra G; Kuster P; Strieth S; Gielen GH; Ring SS; Dietrich J; Pietsch T; Flatz L; Kristiansen G; Landsberg J; Dietrich D
    Clin Epigenetics; 2020 Jun; 12(1):94. PubMed ID: 32586358
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Serum Soluble PD-L1, PD-L2, and B7-H5 as Potential Diagnostic Biomarkers of Human Pancreatic Cancer.
    Wu W; Xia X; Cheng C; Niu L; Wu J; Qian Y
    Clin Lab; 2021 Jun; 67(6):. PubMed ID: 34107622
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients.
    Arrieta O; Montes-Servín E; Hernandez-Martinez JM; Cardona AF; Casas-Ruiz E; Crispín JC; Motola D; Flores-Estrada D; Barrera L
    Oncotarget; 2017 Nov; 8(60):101994-102005. PubMed ID: 29254220
    [TBL] [Abstract][Full Text] [Related]  

  • 91. The Prognostic Impact of PD-L2 in Papillary Renal-Cell Carcinoma.
    Mondorf Y; Mikuteit M; Ivanyi P; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief CG; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Steffens S; Erlmeier F
    Urol Int; 2022; 106(11):1168-1176. PubMed ID: 35654002
    [TBL] [Abstract][Full Text] [Related]  

  • 92. High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients.
    Ludovini V; Bianconi F; Siggillino A; Vannucci J; Baglivo S; Berti V; Tofanetti FR; Reda MS; Bellezza G; Mandarano M; Belladonna ML; Metro G; Chiari R; Sidoni A; Puma F; Minotti V; Roila F
    Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33671892
    [TBL] [Abstract][Full Text] [Related]  

  • 93. PD-L2 based immune signature confers poor prognosis in HNSCC.
    Qiao Y; Liu C; Zhang X; Zhou Q; Li Y; Xu Y; Gao Z; Xu Y; Kong L; Yang A; Mei M; Ren Y; Wang X; Zhou X
    Oncoimmunology; 2021; 10(1):1947569. PubMed ID: 34377590
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications.
    Wolkow N; Jakobiec FA; Afrogheh AH; Eagle RC; Pai SI; Faquin WC
    Am J Ophthalmol; 2019 Apr; 200():226-241. PubMed ID: 30633894
    [TBL] [Abstract][Full Text] [Related]  

  • 95. An Extended PD-L2 Cytoplasmic Domain Results From Alternative Splicing in NSCLC Cells.
    Dietz LL; Furman NT; Larsen TV; Daugaard TF; Thomsen EA; Keller JL; Aagaard L; Sorensen BS; Nielsen AL
    J Immunother; 2022 Nov-Dec 01; 45(9):379-388. PubMed ID: 36036966
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain.
    Shi M; Roemer MG; Chapuy B; Liao X; Sun H; Pinkus GS; Shipp MA; Freeman GJ; Rodig SJ
    Am J Surg Pathol; 2014 Dec; 38(12):1715-23. PubMed ID: 25025450
    [TBL] [Abstract][Full Text] [Related]  

  • 97. PD-L2 expression in senescent cancer cells limits tumor clearance after chemotherapy.
    Nat Cancer; 2024 Mar; 5(3):382-383. PubMed ID: 38332108
    [No Abstract]   [Full Text] [Related]  

  • 98. Effect of Primary Systemic Therapy on PD-1, PD-L1, and PD-L2 mRNA Expression in Advanced Breast Cancer.
    Karsono R; Azhar MA; Pratiwi Y; Saputra F; Nadliroh S; Aryandono T
    Asian Pac J Cancer Prev; 2021 Jul; 22(7):2069-2077. PubMed ID: 34319029
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Programmed death ligand 2 expression plays a limited role in adenocarcinomas of the gastroesophageal junction after preoperative chemotherapy.
    Jomrich G; Kollmann D; Wilfing L; Radosavljevic S; Ramazanova D; Ristl R; Grose RP; Ilhan-Mutlu A; Preusser M; Fassnacht C; Tsai YC; Guenova E; Schoppmann SF
    Eur Surg; 2021; 53(6):287-293. PubMed ID: 34868284
    [TBL] [Abstract][Full Text] [Related]  

  • 100. The Programmed Death Pathway in Ocular Adnexal Sebaceous Carcinoma.
    Bowen RC; Lawson BM; Jody NM; Potter HD; Lucarelli MJ
    Ophthalmic Plast Reconstr Surg; 2020; 36(1):74-79. PubMed ID: 31593039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.